A number of other research firms have also weighed in on EPZM. Zacks Investment Research lowered shares of Epizyme from a buy rating to a hold rating and set a $15.00 price objective on the stock. in a research report on Wednesday, August 14th. Wedbush restated an outperform rating and set a $21.00 target price on shares of Epizyme in a research report on Wednesday, June 12th. HC Wainwright set a $25.00 target price on shares of Epizyme and gave the stock a buy rating in a research report on Monday, June 24th. Finally, Citigroup restated a buy rating on shares of Epizyme in a research report on Thursday, May 30th. Three investment analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Epizyme presently has an average rating of Buy and a consensus target price of $18.11.
NASDAQ:EPZM opened at $12.86 on Wednesday. The firm’s fifty day moving average price is $12.96 and its 200 day moving average price is $12.75. Epizyme has a 1-year low of $5.14 and a 1-year high of $16.59. The company has a debt-to-equity ratio of 0.03, a current ratio of 10.56 and a quick ratio of 10.56. The firm has a market cap of $1.24 billion, a price-to-earnings ratio of -7.48 and a beta of 2.48.
Epizyme (NASDAQ:EPZM) last posted its quarterly earnings data on Friday, August 9th. The biopharmaceutical company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.02). The company had revenue of $5.90 million for the quarter, compared to analysts’ expectations of $0.32 million. During the same quarter last year, the business posted ($0.42) EPS. Epizyme’s revenue was down 50.8% compared to the same quarter last year. As a group, analysts expect that Epizyme will post -2.13 earnings per share for the current fiscal year.
In other Epizyme news, CEO Robert B. Bazemore sold 2,074 shares of the business’s stock in a transaction on Thursday, June 13th. The shares were sold at an average price of $12.10, for a total transaction of $25,095.40. Following the sale, the chief executive officer now directly owns 87,068 shares in the company, valued at approximately $1,053,522.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director David M. Mott sold 104,944 shares of the business’s stock in a transaction on Wednesday, June 26th. The stock was sold at an average price of $13.08, for a total transaction of $1,372,667.52. Following the sale, the director now owns 13,979 shares in the company, valued at $182,845.32. The disclosure for this sale can be found here. Insiders have sold a total of 108,203 shares of company stock worth $1,412,101 over the last 90 days. Insiders own 16.60% of the company’s stock.
Several large investors have recently added to or reduced their stakes in the company. United Services Automobile Association acquired a new position in shares of Epizyme in the 2nd quarter valued at approximately $134,000. Nuveen Asset Management LLC acquired a new position in shares of Epizyme in the 2nd quarter valued at approximately $3,960,000. Price T Rowe Associates Inc. MD raised its position in shares of Epizyme by 57.1% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 635,663 shares of the biopharmaceutical company’s stock valued at $7,978,000 after purchasing an additional 231,109 shares in the last quarter. Victory Capital Management Inc. raised its position in shares of Epizyme by 2.6% in the 2nd quarter. Victory Capital Management Inc. now owns 1,680,830 shares of the biopharmaceutical company’s stock valued at $21,094,000 after purchasing an additional 43,360 shares in the last quarter. Finally, UBS Asset Management Americas Inc. raised its position in shares of Epizyme by 8.4% in the 2nd quarter. UBS Asset Management Americas Inc. now owns 44,935 shares of the biopharmaceutical company’s stock valued at $564,000 after purchasing an additional 3,471 shares in the last quarter. 83.65% of the stock is owned by institutional investors and hedge funds.
Epizyme Company Profile
Epizyme, Inc, a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases primarily in the United States. The company's lead products candidate is tazemetostat, an inhibitor of the EZH2 histone methyltransferase, which is in the Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function; and Phase II clinical trial for adults and Phase I clinical trial for children with epithelioid sarcoma and other INI1-negative solid tumors.
Further Reading: Retained Earnings
Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.